• D-Lin-MC3-DMA for Reliable RNA Delivery Assays

  2026-09-12

  This scenario-driven guide explains how D-Lin-MC3-DMA (SKU A8791) can support controlled siRNA and mRNA lipid nanoparticle experiments while separating carrier effects from genuine cytotoxicity. It combines formulation evidence, storage guidance, assay controls, and vendor-selection criteria for more reproducible laboratory decisions.

• Macromolecular Cryoprotection of THP-1 Monocytes

  2026-09-11

  A 2025 RSC Applied Polymers study shows that polyampholytes combined with controlled ice nucleation can improve post-thaw recovery and macrophage differentiation of THP-1 monocytes in both vials and multi-well plates. The work addresses a major assay-development bottleneck by moving cryopreserved immune cells closer to an assay-ready format while linking improved outcomes to reduced intracellular ice formation.

• CDC42 Polarity Controls Intestinal Stem Cell Fate

  2026-09-11

  Zhang and colleagues show that CDC42-dependent epithelial polarity regulates the intestinal stem cell-to-transit-amplifying cell transition through a YAP/TAZ–epiregulin–mTOR cascade rather than canonical Wnt signaling. Their genetic and pharmacologic rescue experiments connect tissue architecture to crypt proliferation and identify mTOR and EGFR as actionable downstream nodes.

• Mapping KOR Circuits in Opioid Hypersensitivity

  2026-09-10

  A translational framework for using nor-Binaltorphimine dihydrochloride to interrogate κ-opioid receptor signaling in opioid-induced mechanical hypersensitivity and tolerance.

• 3-Hydroxybutyrate (BHBA): Mechanisms & Use

  2026-09-10

  3-hydroxybutyrate (BHBA) is an endogenous ketone body and fatty acid β-oxidation metabolite that links cellular energy status with signaling and chromatin regulation. Its strongest research uses are controlled ketosis modeling, class I HDAC studies, and mechanistic experiments that distinguish BHBA-specific effects from broader ketone-body responses.

• HAX1 Links SARS-CoV-2 Spike to the UPR

  2026-09-09

  The reference study identifies HAX1 as an S1-interacting host factor that mediates SARS-CoV-2 spike-dependent unfolded protein response activation. Its loss abolishes this specialized ER-stress response while worsening spike-associated reactive oxygen species accumulation and mitochondrial dysfunction, providing a mechanistic framework for studying virus–host stress signaling.

• Rgs16::GFP Screening for PDA Chemotherapy

  2026-09-09

  Layeghi-Ghalehsoukhteh and colleagues developed a concerted cell-and-in vivo screening strategy using Rgs16::GFP to identify chemotherapy combinations for pancreatic ductal adenocarcinoma. The study shows that trichostatin A, gemcitabine, and JQ1 produced stronger antitumor effects in combination than selected single agents, while also illustrating how reporter-guided prioritization can connect cell assays with rapid validation in genetically engineered models.

• Verapamil HCl: A Transporter-Aware Assay Guide

  2026-09-08

  Verapamil HCl is more than an L-type calcium channel blocker in translational assays: it can also alter intracellular drug exposure. This guide shows how to distinguish calcium-dependent biology from transporter-related effects in myeloma, apoptosis, and arthritis inflammation studies.

• ATRA Reverses Cisplatin-Linked PARP Resistance in EOC

  2026-09-08

  The reference study shows that all-trans retinoic acid can reduce cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer by suppressing a resistance-associated NAD+ and DNA-repair program. Its sequential cisplatin–ATRA–niraparib strategy provides a mechanistic framework for improving maintenance therapy, while also highlighting the need to validate these findings clinically and across molecular subtypes.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-07

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as a mediator of M2 macrophage polarization in hepatocellular carcinoma through the JAK2/STAT6 axis. Its experimental framework connects tumor-cell extracellular RNA transfer with macrophage phenotyping and provides a basis for testing pathway dependence in tumor–immune communication.

• AG-490 (Tyrphostin B42): JAK2/EGFR Guide

  2026-09-07

  AG-490, also called Tyrphostin B42, is a research tyrosine kinase inhibitor used to interrogate JAK2, EGFR, ErbB2, STAT, and MAPK signaling. Its reported activity supports mechanistic cancer research and immunopathological state suppression, but product-level potency values should not be treated as clinical efficacy.

• 3X FLAG Peptide: Assay Design by Motif Logic

  2026-09-05

  The 3X (DYKDDDDK) Peptide is more than a bright epitope label: its multivalent sequence, antibody recognition, and buffer sensitivity can shape assay performance. This guide combines practical workflow design with motif-level insights from protein interaction biology.

• Palomid 529 (P529) for ESCC Research

  2026-09-04

  Palomid 529 (P529) provides a practical dual-mTORC1/mTORC2 perturbation strategy for studying ESCC signaling, cisplatin resistance, angiogenesis, and radiotherapy response. This workflow connects the RCN2–PPP2CA–PI3K-AKT findings to controlled pharmacology without overstating evidence that has not yet been tested in the reference model.

• ROS-Responsive Lipid Nanoparticles for Mutant RAS

  2026-09-04

  Cai and colleagues developed a combinatorial library of thioketal-containing, ROS-degradable lipids to improve tumor-selective mRNA delivery. Their lead formulation, BAmP-TK-12, delivered DUF5-encoding mRNA to deplete mutant RAS and produced stronger antitumor activity than a small-molecule RAS inhibitor in the reported models.

• Hsa_circ_0136666 Drives Gastric Cancer Immune Escape

  2026-09-03

  Miao et al. identify hsa_circ_0136666 as an oncogenic circular RNA that promotes gastric cancer growth and CD8+ T-cell-dependent immune escape through the miR-375/PRKDC axis. The study connects PRKDC-dependent PD-L1 phosphorylation with impaired checkpoint protein degradation and shows that LNP-delivered siRNA can improve anti-PD-L1 treatment responses in tumor models.

8051 records 1/537 page Next 12345 下5页 Last page